Bone Biologics faces Nasdaq delisting risk after shares stay below $1 bid price threshold

• Nasdaq flagged Bone Biologics for failing to meet the $1 minimum bid-price rule, based on 30 consecutive business days of closing bids.
• The company has until March 9, 2027 to regain compliance by posting a closing bid of at least $1 for 10 straight sessions.
• Failure to cure could trigger a delisting notice, with the option to appeal to a Nasdaq hearings panel.
• Management plans to seek shareholder approval for a reverse stock split at its annual meeting to lift the share price.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-042940), on September 16, 2026, and is solely responsible for the information contained therein.